This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Iovance Biotherapeutics (IOVA) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.
Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil
by Zacks Equity Research
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
First-Mover Pandemic Disease Fight ETF On The Way
by Sweta Killa
Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.
Do Options Traders Know Something About Iovance Biotherapeutics (IOVA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Iovance Biotherapeutics (IOVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
Cancer-Fighting Stocks & ETF: What You Need to Know
by Neena Mishra
Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference
Why Cancer-Fighting Stocks & ETFs Are Soaring
by Neena Mishra
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Lion Biotechnologies (IOVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Lion Biotechnologies (IOVA) stock based on the movements in the options market lately.
Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1%
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
Is a Surprise Coming for Lion Biotechnologies (IOVA) This Earnings Season?
by Zacks Equity Research
Lion Biotechnologies (IOVA) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) shares rose more than 5% in the last trading session, amid huge volumes.